Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in Bullous Pemphigoid
NCT01688882Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of ligelizumab in Bullous Pemphigoid (BP), sponsored by Novartis. Started Jan 2013; status: terminated.
02
Drugs
ligelizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT01688882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01688882.